Scope: Using surrogate outcome biomarkers as endpoints in Parkinson's disease (PD) trials may help differentiate symptomatic effects of putative neuroprotective agents from true disease-modification. We undertook a systematic review to assess what biomarkers for disease progression in PD exist.Searc